The utility of modeling and simulation in drug development and regulatory review

#	Paper	IF	Citations
173	Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. *CPT: Pharmacometrics and Systems Pharmacology*, **2013**, 2, e63	4.5	271
172	Integrative analysis of transporter-mediated drug-drug interactions. **2014**, 29, 426-438		
171	Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. *CPT: Pharmacometrics and Systems Pharmacology*, **2014**, 3, e88	4.5	132
170	Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy. *Clinical Pharmacology and Therapeutics*, **2014**, 95, 478-80	6.1	40
169	PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways. *Clinical Pharmacology and Therapeutics*, **2014**, 95, 550-7	6.1	45
168	Letter to the Editor Regarding "Virtual Screening of Natural and Synthetic Ligands Against Diabetic Retinopathy by Molecular Interaction With Angiopoietin-2". **2014**, 3, 395-6		
167	Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine. *European Journal of Pharmaceutical Sciences*, **2014**, 57, 240-9	5.1	34
166	The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement. **2014**, 10, 631-5		18
165	Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition. *CPT: Pharmacometrics and Systems Pharmacology*, **2014**, 3, e138	4.5	12
164	Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients. *AAPS Journal*, **2014**, 16, 1018-28	3.7	39
163	A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. *Clinical Pharmacokinetics*, **2014**, 53, 625-36	6.2	80
162	On-line sequential injection-capillary electrophoresis for near-real-time monitoring of extracellular lactate in cell culture flasks. **2014**, 1323, 157-62		21
161	Regulatory Science Perspectives on Transporter Studies in Drug Development. **2014**, 473-490		2
160	Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. *CPT: Pharmacometrics and Systems Pharmacology*, **2014**, 3, e150	4.5	95
159	In silico ADME/T modelling for rational drug design. **2015**, 48, 488-515		137
158	Catalyzing the Critical Path Initiative: FDA's progress in drug development activities. *Clinical Pharmacology and Therapeutics*, **2015**, 97, 221-33	6.1	25
157	Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. *Biopharmaceutics and Drug Disposition*, **2015**, 36, 148-62	1.7	7

138	Role of Systems Modeling in Regulatory Drug Approval. *AAPS Advances in the Pharmaceutical Sciences Series*, **2016**, 15-25	0.5	1
137	Perspectives in regulatory science: translational and clinical pharmacology. **2016**, 21-22, 67-73		2
136	Toward Understanding Drug Release From Biodegradable Polymer Microspheres of Different Erosion Kinetics Modes. *Journal of Pharmaceutical Sciences*, **2016**, 105, 1934-1946	3.9	4
135	Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance. **2016**, 2, 161-169		147
134	An integrative test strategy for cancer hazard identification. **2016**, 46, 615-39		25
133	Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model. **2016**, 44, 821-32		58
132	Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. *European Journal of Pharmaceutical Sciences*, **2016**, 89, 73-82	5.1	12
131	Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. **2016**, 43, 481-504		56
130	The Personalization of Drug Therapy for Elderly Patients. *AAPS Advances in the Pharmaceutical Sciences Series*, **2016**, 589-611	0.5	
129	Applications of Physiologically Based Pharmacokinetic (PBPK) Models for Pediatric Populations. **2016**, 109-125		2
128	Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and Simulations. **2016**, 2, 171-177		14
127	Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro data. **2016**, 31, 224-33		42
126	Physics-Based Modeling of Chemical Hazards in a Regulatory Framework: Comparison with Quantitative Structure Property Relationship (QSPR) Methods for Impact Sensitivities. **2016**, 55, 7569-7577		21
125	Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside. **2016**, 12, 253-65		8
124	In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells. **2016**, 44, 297-307		34
123	In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically Based Absorption Models. **2016**, 13, 1763-78		52
122	Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development. **2016**, 44, 934-43		24
121	Definition and validation of a patient-individualized physiologically-based pharmacokinetic model. **2016**, 84, 394-408		19

120	A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients. **2017**, 45, 361-374		14
119	Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon. *Biopharmaceutics and Drug Disposition*, **2017**, 38, 94-114	1.7	27
118	Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions. **2017**, 45, 390-398		24
117	Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities. **2017**, 3, 36-49		24
116	Global Proteomic Analysis of Human Liver Microsomes: Rapid Characterization and Quantification of Hepatic Drug-Metabolizing Enzymes. **2017**, 45, 666-675		33
115	Analysis of the Change in the Blood Concentration-Time Profile Caused by Complex Drug-Drug Interactions in the Liver Considering the Enterohepatic Circulation: Examining Whether the Inhibition Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the Analyses Using Physiologically Based Pharmacokinetic Modeling. *Journal of Pharmaceutical Sciences*	3.9	3
114	Enterohepatic Circulation Effect in Physiologically Based Pharmacokinetic Models: The Sorafenib Case. **2017**, 56, 3156-3166		9
113	Clinical Drug-Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access. *Journal of Pharmaceutical Sciences*, **2017**, 106, 2214-2218	3.9	29
112	Optimizing drug development in oncology by clinical trial simulation: Why and how?. **2018**, 19, 1203-1217		6
111	Extrapolation of Elementary Rate Constants of P-glycoprotein-Mediated Transport from MDCKII-hMDR1-NKI to Caco-2 Cells. **2017**, 45, 190-197		8
110	Medicines for Pediatric Patients-Biopharmaceutical, Developmental, and Regulatory Considerations. *Journal of Pharmaceutical Sciences*, **2017**, 106, 950-960	3.9	10
109	Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling. **2017**, 40, 1356-1379		36
108	Enhancing the Pediatric Drug Development Framework to Deliver Better Pediatric Therapies Tomorrow. **2017**, 39, 1920-1932		21
107	Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions. **2017**, 45, 1304-1316		20
106	Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions. **2017**, 45, 1156-1165		20
105	Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective. *CPT: Pharmacometrics and Systems Pharmacology*, **2017**, 6, 413-415	4.5	34
104	Discovery and Pharmacokinetic⊇Pharmacodynamic Evaluation of an Orally Available Novel Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1. **2017**, 519-543		1
103	Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects. **2017**, 34, 1584-1600		12

102	Letter to the Editor, Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans. *Biopharmaceutics and Drug Disposition*, **2017**, 38, 443-444	1.7	
101	IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results. *European Journal of Pharmaceutical Sciences*, **2017**, 96, 610-625	5.1	43
100	IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds. *European Journal of Pharmaceutical Sciences*, **2017**, 96, 598-609	5.1	30
99	Allometry Is a Reasonable Choice in Pediatric Drug Development. *Journal of Clinical Pharmacology*, **2017**, 57, 469-475	2.9	24
98	Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics. **2017**, 8, 651		16
97	Humans Vary, So Cardiac Models Should Account for That Too!. **2017**, 8, 700		3
96	Nonstandard Finite Difference Method Applied to a Linear Pharmacokinetics Model. **2017**, 4,		8
95	Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug-Drug Interactions Involving Enzyme Modulation. *Clinical Pharmacokinetics*, **2018**, 57, 1337-1346	6.2	13
94	Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data. *British Journal of Clinical Pharmacology*, **2018**, 84, 1335-1345	3.8	9
93	Regulatory Perspectives in Pharmacometric Models of Osteoporosis. *Journal of Clinical Pharmacology*, **2018**, 58, 572-585	2.9	7
92	[Dynamic Simulation of Drug-Drug Interactions by Using Multi-level Physiological Modeling & Simulation Platforms]. **2018**, 138, 347-351		1
91	Computational modeling of human oral bioavailability: what will be next?. **2018**, 13, 509-521		21
90	Pediatric Dose Selection and Utility of PBPK in Determining Dose. *AAPS Journal*, **2018**, 20, 31	3.7	32
89	Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter-Enzyme Interplay. **2018**, 46, 680-691		11
88	Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making. **2018**, 162, 341-348		39
87	Challenges and Opportunities in the Development of Medical Therapies for Pediatric Populations and the Role of Extrapolation. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 419-433	6.1	22
86	Model-based drug development: application of modeling and simulation in drug development. **2018**, 48, 431-441		23
85	Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. *AAPS Journal*, **2018**, 20, 46	3.7	30

#	Reference	IF	Cit.
84	Current strategies to streamline pharmacotherapy for older adults. *European Journal of Pharmaceutical Sciences*, **2018**, 111, 432-442	5.1	10
83	Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling. **2018**, 122, 331-340		21
82	Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 505-514	6.1	10
81	Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. *Journal of Clinical Pharmacology*, **2018**, 58, 485-493	2.9	9
80	An in silico approach to determine challenges in the bioavailability of ciprofloxacin, a poorly soluble weak base with borderline solubility and permeability characteristics. *European Journal of Pharmaceutics and Biopharmaceutics*, **2018**, 122, 186-196	5.7	17
79	A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide. *CPT: Pharmacometrics and Systems Pharmacology*, **2018**, 7, 829-837	4.5	2
78	Application of PK-PD Modeling and Simulation Approaches for Immuno-Oncology Drugs. **2018**, 207-222		2
77	Translational Modeling and Simulation for Molecularly Targeted Small Molecule Anticancer Agents: Case Studies of Multiple Tyrosine Kinase Inhibitors, Crizotinib and Lorlatinib. **2018**, 433-466		1
76	Maximizing the impact of microphysiological systems with in vitro-in vivo translation. **2018**, 18, 1831-1837		38
75	The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling. *Clinical Pharmacokinetics*, **2019**, 58, 189-211	6.2	21
74	Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice. **2019**, 203, 107397		13
73	Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort. *Clinical Pharmacokinetics*, **2019**, 58, 911-926	6.2	12
72	Pharmacometrics and systems pharmacology for metabolic bone diseases. *British Journal of Clinical Pharmacology*, **2019**, 85, 1136-1146	3.8	8
71	Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them. *Clinical Pharmacokinetics*, **2019**, 58, 1355-1371	6.2	20
70	The US Food and Drug Administration's Model-Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 74-78	6.1	14
69	Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release Products. *Journal of Clinical Pharmacology*, **2019**, 59, 1252-1263	2.9	11
68	Emerging Role of Organ-on-a-Chip Technologies in Quantitative Clinical Pharmacology Evaluation. *Clinical and Translational Science*, **2019**, 12, 113-121	4.9	21
67	Monoclonal Antibodies and Fc-Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration. *Journal of Clinical Pharmacology*, **2019**, 59, 1130-1143	2.9	16

66	Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs. *Pharmaceutics*, **2019**, 11,	6.4	30
65	A Holistic and Integrative Approach for Advancing Model-Informed Drug Development. *CPT: Pharmacometrics and Systems Pharmacology*, **2019**, 8, 9-11	4.5	21
64	Parameter Uncertainty Analysis of a Mathematical Ion Channel Model. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2019**, 2019, 1952-1955	0.9	
63	Generating Model Integrated Evidence for Generic Drug Development and Assessment. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 338-349	6.1	19
62	Model Informed Drug Development and Regulation in China: Challenges and Opportunities. *CPT: Pharmacometrics and Systems Pharmacology*, **2019**, 8, 59-61	4.5	5
61	A Survey of Software Tool Utilization and Capabilities for Quantitative Systems Pharmacology: What We Have and What We Need. *CPT: Pharmacometrics and Systems Pharmacology*, **2019**, 8, 62-76	4.5	9
60	Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 134, 117-125	5.7	15
59	Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology. *Journal of Pharmaceutical Sciences*, **2019**, 108, 21-25	3.9	135
58	Fifty-Eight Years and Counting: High-Impact Publishing in Computational Pharmaceutical Sciences and Mechanism-Based Modeling. *Journal of Pharmaceutical Sciences*, **2019**, 108, 2-7	3.9	2
57	Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development. *Clinical Pharmacology in Drug Development*, **2019**, 8, 418-425	2.3	16
56	Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 1018-1030	6.1	9
55	Comparing Model Performance in Characterizing the PK/PD of the Anti-Myostatin Antibody Domagrozumab. *Clinical and Translational Science*, **2020**, 13, 125-136	4.9	1
54	Clinical Applications of Physiologically Based Pharmacokinetic Modeling: Perspectives on the Advantages and Challenges. *Therapeutic Drug Monitoring*, **2020**, 42, 157-158	3.2	4
53	Mechanisms and clinical relevance of pharmacokinetic-based clinical drug-drug interactions for drugs recently approved by the US Food and Drug Administration. **2020**, 339-358		
52	Regulatory Science to Promote Access to Intrauterine Systems for Women in the United States. *Journal of Clinical Pharmacology*, **2020**, 60 Suppl 2, S34-S38	2.9	2
51	Review of Complex Generic Drugs Delivered Through the Female Reproductive Tract: The Current Competitive Landscape and Emerging Role of Physiologically Based Pharmacokinetic Modeling to Support Development and Regulatory Decisions. *Journal of Clinical Pharmacology*, **2020**, 60 Suppl 2, S26-S33	2.9	1
50	Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia. *Saudi Pharmaceutical Journal*, **2020**, 28, 1217-1227	4.4	1
49	A history and recent efforts of selected physiologically based pharmacokinetic modeling topics. **2020**, 1-26		3

48	Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 575-585	6.1	7
47	Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. *Journal of Clinical Pharmacology*, **2020**, 60, 915-930	2.9	19
46	Sampling Site Has a Critical Impact on Physiologically Based Pharmacokinetic Modeling. *Journal of Pharmacology and Experimental Therapeutics*, **2020**, 372, 30-45	4.7	10
45	Resolving Clinical Phenotypes into Endotypes in Allergy: Molecular and Omics Approaches. *Clinical Reviews in Allergy and Immunology*, **2021**, 60, 200-219	12.3	10
44	On precision dosing of oral small molecule drugs in oncology. *British Journal of Clinical Pharmacology*, **2021**, 87, 263-270	3.8	0
43	Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities. *European Journal of Pharmaceutical Sciences*, **2021**, 158, 105648	5.1	6
42	Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms. *Biopharmaceutics and Drug Disposition*, **2021**, 42, 107-117	1.7	15
41	Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs. *AAPS Journal*, **2021**, 23, 31	3.7	6
40	Physiologically-based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**, 10, 399-411	4.5	9
39	Clinical Development ⊡A Primer. 1-25		
38	Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment. *Biopharmaceutics and Drug Disposition*, **2021**, 42, 263-284	1.7	1
37	Design and conduct considerations for studies in patients with impaired renal function. *Clinical and Translational Science*, **2021**, 14, 1689-1704	4.9	2
36	Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations. *Journal of Clinical Pharmacology*, **2021**, 61 Suppl 1, S175-S187	2.9	3
35	Physiologically-Based Pharmacokinetic Modeling to Support Determination of Bioequivalence for Dermatological Drug Products: Scientific and Regulatory Considerations. *Clinical Pharmacology and Therapeutics*, **2021**,	6.1	3
34	Predictive Performance of Physiologically Based Pharmacokinetic Models for the Effect of Food on Oral Drug Absorption: Current Status. *CPT: Pharmacometrics and Systems Pharmacology*, **2018**, 7, 82-89	4.5	50
33	The Role of Transporters in Drug Development: Regulatory Science Perspectives from the FDA. *AAPS Advances in the Pharmaceutical Sciences Series*, **2013**, 257-283	0.5	2
32	QSAR/QSPR Modeling in the Design of Drug Candidates with Balanced Pharmacodynamic and Pharmacokinetic Properties. *Challenges and Advances in Computational Chemistry and Physics*, **2017**, 339-384	0.7	2
31	Pharmacokinetic Modeling in Nano-formulations: Concept, Implementation and Challenges. *Current Pharmaceutical Design*, **2018**, 24, 5175-5180	3.3	5

30	Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK. *Recent Patents on Anti-Cancer Drug Discovery*, **2019**, 14, 177-186	2.6	7
29	CHAPTER 13:Drug–Drug Interactions: Computational Approaches. *RSC Drug Discovery Series*, **2015**, 283-308	0.6	
28	Mechanistic Physiologically Based Pharmacokinetic Models in Development of Therapeutic Monoclonal Antibodies. 1-16		
27	IN SILICO MODELING OF METABOLITE KINETICS. 213-237		
26	Role of ADMET Tools in Current Scenario: Application and Limitations. **2020**, 71-87		3
25	Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends. *Frontiers in Pharmacology*, **2021**, 12, 708299	5.6	5
24	Compartmental analysis of drug distribution. **2022**, 27-42		
23	Pharmacogenomic mechanisms of drug toxicity. **2022**, 303-322		
22	Applications of Pediatric PBPK Modeling: Current Status for Drug Development Processes and Use in Clinical Settings. *Japanese Journal of Clinical Pharmacology and Therapeutics*, **2020**, 51, 267-276	0	
21	Applications of PBPK Modeling and Simulations in The Clinical Pharmacology Field: Lessons from Several Case Studies. *Japanese Journal of Clinical Pharmacology and Therapeutics*, **2020**, 51, 331-344	0	
20	Predicting perfect drug candidates: Molecular docking 2.0. *Journal of Pharmacy and Bioallied Sciences*, **2014**, 6, 137-8	1.1	1
19	A New Model to Describe the Single-dose Pharmacokinetics of Bevacizumab and Predict Its Multiple-Dose Pharmacokinetics in Beagle Dogs. *Iranian Journal of Pharmaceutical Research*, **2019**, 18, 1147-1155	1.1	
18	Concepts of advanced therapeutic delivery systems for the management of remodeling and inflammation in airway diseases.. *Future Medicinal Chemistry*, **2022**,	4.1	1
17	Mechanistic modelling of enzyme-restoration effects for new recombinant liver-targeted proteins in acute intermittent porphyria.. *British Journal of Pharmacology*, **2022**,	8.6	
16	FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review.. *Cancers*, **2021**, 14,	6.6	4
15	A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.. *European Journal of Drug Metabolism and Pharmacokinetics*, **2022**,	2.7	0
14	Application of Physiologically Based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs. *Frontiers in Pharmacology*, **2022**, 13,	5.6	1
13	Physiologically Based Pharmacokinetic (PBPK) Modelling. **2022**, 255-284		

12	Multi-phase Multi-Layer Mechanistic Dermal Absorption (MPML MechDermA) Model to predict local and systemic exposure of drug products applied on skin. *CPT: Pharmacometrics and Systems Pharmacology,*	4.5	1
11	Computational modeling of protracted HCMV replication using genome substrates and protein temporal profiles. **2022**, 119,		0
10	Pharmacometrics: The Already-Present Future of Precision Pharmacology.		
9	Cytochrome P450 enzymes in the pediatric population: Connecting knowledge on P450 expression with pediatric pharmacokinetics. **2022**, 365-391		0
8	Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy.		0
7	Case Study on Certara Simcyp PBPK Simulator to Eliminate Lengthy Clinical Trails. 69-109		3
6	Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy.		1
5	Therapeutic Protein Drug Interactions: A White Paper from the International Consortium for Innovation and Quality in Pharmaceutical Development.		0
4	Quantitative CYP3A4 induction risk assessment using human hepatocytes complemented with pregnane X receptor (PXR)-activating profiles. DMD-AR-2022-001132		0
3	Pharmacokinetics of Novel Furoxan/Coumarin Hybrids in Rats Using LC-MS/MS Method and Physiologically Based Pharmacokinetic Model. **2023**, 28, 837		0
2	In-Depth Analysis of Physiologically Based Pharmacokinetic (PBPK) Modeling Utilization in Different Application Fields Using Text Mining Tools. **2023**, 15, 107		0
1	Application of a physiologically based pharmacokinetic model in predicting captopril disposition in children with chronic kidney disease. **2023**, 13,		0